Insulin Lispro
Brand names: Admelog Solostar, Humalog, Humalog Junior Kwikpen, Humalog Kwikpen U-100, Insulin Lispro, Admelog, Humalog Kwikpen U-200, Humalog Tempo Pen U-100, Insulin Lispro Junior Kwikpen, Insulin Lispro Kwikpen U-100
Part of: Insulin
At a glance
- Medicare prescriptions, 2024
- 2,081,959
- Medicare drug cost
- $523.4M
- Average cost per prescription
- $251
- Clinicians who prescribed it
- 45,034
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
HUMALOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
From the FDA-approved prescribing information (label dated June 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Endocrinology & Diabetes 28.3%
- Internal Medicine 22.3%
- Nurse Practitioners 18.7%
- Family Medicine 17.5%
- Physician Assistants 5.3%
- Geriatric Medicine 2.1%
- General Practice 2.1%
- Hospitalist 0.9%
- Pharmacists 0.7%
- Nephrology (Kidney) 0.5%
- Pulmonology 0.2%
- Emergency Medicine 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 18% from 2019 to 2024.
Biggest change by state since 2019
- Louisiana +99%
- Minnesota +84%
- Mississippi +77%
- Nebraska +56%
- Iowa +54%
- Delaware (smallest change) −22%
- Maine (smallest change) −5%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $45 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Lilly USA, LLC $45
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- Mar 2024 · Eli Lilly & Company · Class II
CGMP Deviations - Apr 2023 · Sanofi-Aventis U.S. LLC · Class II
Lack of Assurance of Sterility: Malformed crimped collar seal - Apr 2022 · Cardinal Health Inc. · Class I
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.